WS016治疗中国高钾血症患者的随机双盲试验
达到正常血钾者再随机接受每日一次WS016或安慰剂维持12天。主要终点为急性期和维持期血清钾相对基线的指数变化率。结果显示急性期WS016 12g组血钾下降率显著优于安慰剂,维持期各WS016组血钾日升幅数值上低于安慰剂但未达统计学显著。
要点
- 急性期WS016 12g组血钾下降率0.33%/小时,显著优于安慰剂0.13%/小时(P<0.0001)。
- 维持期WS016 12g组血钾日升幅0.90%,安慰剂1.24%,差值-0.34%(95%CI -1.30%至0.63%;P=0.49)。
- 不良事件发生率急性期WS016组26.9% vs 安慰剂20.0%,维持期27.0% vs 31.3%。
核心结论
- WS016可快速降低血清钾水平,并使更多患者维持正常血钾范围。
研究设计与样本
- 达到正常血钾者再随机接受WS016 3g、6g、12g或安慰剂每日一次维持12天。
- 主要终点为急性期和维持期血清钾相对基线的指数变化率。
主要发现
- 急性期WS016 3g、6g、12g组血钾平均指数下降率分别为0.19%/小时(P=0.27)、0.17%/小时(P=0.35)、0.33%/小时(P<0.0001),安慰剂组为0.13%/小时。
- 维持期WS016 12g组血钾日升幅0.90%,安慰剂组1.24%,差值-0.34%(95%CI -1.30%至0.63%;P=0.49)。
- 急性期不良事件发生率WS016组26.9%,安慰剂组20.0%;维持期分别为27.0%和31.3%。
临床怎么用
- WS016 12g每日三次可在48小时内显著加速血钾下降,可用于高钾血症急性降钾治疗。
- 维持期WS016各剂量虽数值上减缓血钾回升,但未达统计学显著,需结合临床个体化决策。
局限性
- 维持期血钾日升幅差异未达统计学显著(P=0.49),证据强度有限。
- 研究仅纳入中国高钾血症患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: WS016 is a highly selective cation exchanger which traps potassium in the intestinal tract, reducing serum potassium levels in patients with hyperkalemia. This study aimed to evaluate the efficacy and safety of WS016 in hyperkalemic patients. METHODS: One hundred forty eligible patients were randomized to receive either WS016 (3 g, 6 g, or 12 g), thrice daily, or placebo for 48 hours. Among those who achieved normokalemia, patients were randomized to WS016 (3 g, 6 g, and 12 g), once daily for 12 days. The primary outcome was the exponential rate of change in serum potassium levels from baseline over the acute and maintenance treatment period, respectively. RESULTS: During the acute treatment phase, the mean exponential rates of reduction from baseline were 0.19% (P = 0.27), 0.17% (P = 0.35), and 0.33% (P < 0.0001) per hour in the WS016 3 g, 6 g, and 12 g group, respectively, compared with a 0.13% with placebo. In contrast, during the maintenance phase, all WS016 groups showed a numerically slower mean daily increase in serum potassium compared with their corresponding placebo groups. The daily increase rate was 0.90% with WS016 12 g versus 1.24% with placebo, the difference was -0.34% (95% confidence interval [CI]: -1.30% to 0.63%; P = 0.49). The overall incidence of adverse events was comparable between WS016 and placebo groups as follows: 26.9% (WS016) versus 20.0% (placebo) during the acute phase and 27.0% versus 31.3% in the maintenance phase. CONCLUSION: WS016 reduced serum potassium levels rapidly and maintained more patients within the normokalemic range.
引用
- Sui Z, Zhao J, Ji ZH, et al. Randomized Double-Blind Trial of WS016 in Chinese Patients With Hyperkalemia. Kidney Int Rep. 2026. PMID: 41853744. doi:10.1016/j.ekir.2026.106358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。